JP6441320B2 - がん治療のための予測的バイオマーカー - Google Patents
がん治療のための予測的バイオマーカー Download PDFInfo
- Publication number
- JP6441320B2 JP6441320B2 JP2016515715A JP2016515715A JP6441320B2 JP 6441320 B2 JP6441320 B2 JP 6441320B2 JP 2016515715 A JP2016515715 A JP 2016515715A JP 2016515715 A JP2016515715 A JP 2016515715A JP 6441320 B2 JP6441320 B2 JP 6441320B2
- Authority
- JP
- Japan
- Prior art keywords
- tlr
- agonist
- treatment
- cells
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
Description
Claims (14)
- 治療の開始に先立ってCD3+ CD56+ CD69+活性化ナチュラルキラーT(NKT)細胞の頻度を決定することにより、がんに冒された患者がTLR−9アゴニストによる治療に応答するであろうかまたは応答するかを予測またはモニターする方法であって、前記頻度が、全NKT細胞集団のCD3+ CD56+ CD69+活性化NKT細胞の頻度であり、前記TLR−9アゴニストが、少なくとも1つの配列モチーフN1N2CGN3N4を含むDNAコンストラクトであり、ここでN1N2およびN3N4はA、C、TおよびGの任意の組合せであり、Cはデオキシシチジンであり、Gはデオキシグアノシンであり、Aはデオキシアデノシンであり、Tはデオキシチミジンであり、前記DNAコンストラクトは、共有結合的に閉じた部分的に自己相補的なものであり、二本鎖ステム及び一本鎖末端ループを備え、前記一本鎖末端ループは、前記配列モチーフN1N2CGN3N4を少なくとも1つ備えている、前記方法。
- TLR−9アゴニストによる治療の応答者が、全NKT細胞集団のCD3+ CD56+ CD69+活性化NKT細胞の少なくとも3%の頻度を有する、請求項1に記載の方法。
- 先立って非DNA薬物による導入療法が行われた、請求項1または2に記載の方法。
- 前記TLR−9アゴニストがMGN1703である、請求項1から3のいずれか一項に記載の方法。
- TLR−9アゴニストを有効成分として含有する、全ナチュラルキラーT(NKT)細胞集団のCD3+ CD56+ CD69+活性化NKT細胞のレベルが治療の開始に先立って上昇している患者のがん治療に用いる組成物であって、前記TLR−9アゴニストが、少なくとも1つの配列モチーフN1N2CGN3N4を含むDNAコンストラクトを少なくとも含んでなり、ここでN1N2およびN3N4はA、C、TおよびGの任意の組合せであり、Cはデオキシシチジンであり、Gはデオキシグアノシンであり、Aはデオキシアデノシンであり、Tはデオキシチミジンであり、前記DNAコンストラクトは、共有結合的に閉じた部分的に自己相補的なものであり、二本鎖ステム及び一本鎖末端ループを備え、前記一本鎖末端ループは、前記配列モチーフN1N2CGN3N4を少なくとも1つ備えている、前記組成物。
- N1N2がGT、GG、GA、ATまたはAAを含む群から選択される要素であり、N3N4がCTまたはTTを含む群から選択される要素である、請求項5に記載の組成物。
- 前記TLR−9アゴニストが少なくとも1つのL−DNAヌクレオチドを含む、請求項5または6に記載の組成物。
- 前記TLR−9アゴニストがMGN1703である、請求項5または6に記載の組成物。
- 前記TLR−9アゴニストの少なくとも1つのヌクレオチドが、カルボキシル、アミン、アミド、アルジミン、ケタール、アセタール、エステル、エーテル、ジスルフィド、チオールおよびアルデヒド基を含む群から選択される官能基により修飾されている、請求項5から8のいずれか一項に記載の組成物。
- 前記DNAコンストラクトが、ペプチド、タンパク質、炭水化物、抗体、脂質、ミセル、ベシクル、合成分子、ポリマー、マイクロプロジェクタイル、金属粒子、ナノ粒子または固相を含む群から選択される化合物に連結している、請求項5から9のいずれか一項に記載の組成物。
- 前記DNAコンストラクトが医薬組成物の一部である、請求項5から10のいずれか一項に記載の組成物。
- 前記医薬組成物がワクチンである、請求項11に記載の組成物。
- 全ナチュラルキラーT(NKT)細胞集団のCD3+ CD56+ CD69+活性化NKT細胞の頻度を検出および定量するための蛍光標識抗体を含む、がんに冒された患者がTLR−9アゴニストによる治療に応答するであろうかまたは応答するかを治療の開始に先立って予測またはモニターするためのキットであって、前記TLR−9アゴニストが、少なくとも1つの配列モチーフN1N2CGN3N4を含むDNAコンストラクトであり、ここでN1N2およびN3N4はA、C、TおよびGの任意の組合せであり、Cはデオキシシチジンであり、Gはデオキシグアノシンであり、Aはデオキシアデノシンであり、Tはデオキシチミジンであり、前記DNAコンストラクトは、共有結合的に閉じた部分的に自己相補的なものであり、二本鎖ステム及び一本鎖末端ループを備え、前記一本鎖末端ループは、前記配列モチーフN1N2CGN3N4を少なくとも1つ備えている、前記キット。
- 前記TLR−9アゴニストがMGN1703である、請求項13に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1309657.3 | 2013-05-30 | ||
GB1309657.3A GB2514591A (en) | 2013-05-30 | 2013-05-30 | Predictive biomarker for cancer therapy |
PCT/EP2014/059995 WO2014191222A1 (en) | 2013-05-30 | 2014-05-15 | Predictive biomarker for cancer therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016526164A JP2016526164A (ja) | 2016-09-01 |
JP6441320B2 true JP6441320B2 (ja) | 2018-12-19 |
Family
ID=48805478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016515715A Expired - Fee Related JP6441320B2 (ja) | 2013-05-30 | 2014-05-15 | がん治療のための予測的バイオマーカー |
Country Status (18)
Country | Link |
---|---|
US (1) | US10006032B2 (ja) |
EP (1) | EP3004875B1 (ja) |
JP (1) | JP6441320B2 (ja) |
KR (1) | KR101937442B1 (ja) |
CN (2) | CN110201156A (ja) |
AU (1) | AU2014273400B2 (ja) |
BR (1) | BR112015029852A2 (ja) |
CA (1) | CA2907980A1 (ja) |
DK (1) | DK3004875T3 (ja) |
ES (1) | ES2795929T3 (ja) |
GB (1) | GB2514591A (ja) |
HK (1) | HK1216779A1 (ja) |
IL (1) | IL242551A (ja) |
MX (1) | MX365512B (ja) |
PL (1) | PL3004875T3 (ja) |
RU (1) | RU2672358C2 (ja) |
WO (1) | WO2014191222A1 (ja) |
ZA (1) | ZA201506813B (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015187966A1 (en) | 2014-06-04 | 2015-12-10 | Aurasense Therapeutics, Llc | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
EP3392345A1 (en) | 2017-04-22 | 2018-10-24 | Mologen AG | Biomarker for small cell lung cancer therapy |
WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
JP2020531555A (ja) * | 2017-08-31 | 2020-11-05 | モロゲン・アーゲー | 腫瘍微小環境のモジュレーションのためのtlr−9アゴニスト |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0314682D0 (en) * | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
WO2006015560A1 (de) | 2004-08-09 | 2006-02-16 | Mologen Ag | Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen |
US20090220931A1 (en) * | 2005-09-08 | 2009-09-03 | Mologen Ag | Functional in vitro immunoassay |
JP2010512421A (ja) * | 2006-12-12 | 2010-04-22 | イデラ ファーマシューティカルズ インコーポレイテッド | Tlr9の合成アゴニスト |
JP5357782B2 (ja) * | 2007-02-21 | 2013-12-04 | バクシネックス インコーポレーティッド | 抗原負荷CD1d分子によるNKT細胞活性の調節 |
AU2008282172B2 (en) * | 2007-08-01 | 2014-05-22 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of TLR9 |
JP2010536787A (ja) * | 2007-08-15 | 2010-12-02 | イデラ ファーマシューティカルズ インコーポレイテッド | Toll様受容体モジュレータ |
JP5809415B2 (ja) * | 2007-11-09 | 2015-11-10 | ペレグリン ファーマシューティカルズ,インコーポレーテッド | 抗vegf抗体の組成物および方法 |
EP2073009A1 (en) * | 2007-12-19 | 2009-06-24 | Cell Med Research GMBH | Method for T, NK and NKT cells |
EP2711021B1 (en) | 2008-05-02 | 2016-03-09 | BliNK Therapeutics Limited | Products and methods for stimulating an immune response |
WO2009138494A2 (en) * | 2008-05-15 | 2009-11-19 | Ablynx N.V. | Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors |
GB0820698D0 (en) * | 2008-11-12 | 2008-12-17 | Ludwig Inst Cancer Res | Uses of immunomodulators |
CN102421448A (zh) * | 2009-05-29 | 2012-04-18 | 霍夫曼-拉罗奇有限公司 | Her2信号传导调控剂在表达her2的胃癌患者中 |
KR102100110B1 (ko) * | 2010-11-19 | 2020-04-14 | 이데라 파마슈티칼즈, 인코포레이티드 | 톨-유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고뉴클레오타이드(iro) 화합물 |
GB201021867D0 (en) * | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
SI2744826T1 (sl) * | 2011-08-16 | 2022-05-31 | Morphosys Ag | Kombinirana terapija s protitelesom proti CD19 in analogom purina |
EP2682750A1 (en) * | 2012-07-02 | 2014-01-08 | Sotio a.s. | In vitro method for the diagnosis and surveillance of cancer |
-
2013
- 2013-05-30 GB GB1309657.3A patent/GB2514591A/en not_active Withdrawn
-
2014
- 2014-05-15 MX MX2015016305A patent/MX365512B/es active IP Right Grant
- 2014-05-15 US US14/891,869 patent/US10006032B2/en active Active
- 2014-05-15 CA CA2907980A patent/CA2907980A1/en not_active Abandoned
- 2014-05-15 CN CN201910417409.6A patent/CN110201156A/zh active Pending
- 2014-05-15 DK DK14725114.4T patent/DK3004875T3/da active
- 2014-05-15 RU RU2015150739A patent/RU2672358C2/ru not_active Application Discontinuation
- 2014-05-15 KR KR1020157029934A patent/KR101937442B1/ko active IP Right Grant
- 2014-05-15 CN CN201480024805.8A patent/CN105247365B/zh not_active Expired - Fee Related
- 2014-05-15 PL PL14725114T patent/PL3004875T3/pl unknown
- 2014-05-15 AU AU2014273400A patent/AU2014273400B2/en not_active Ceased
- 2014-05-15 WO PCT/EP2014/059995 patent/WO2014191222A1/en active Application Filing
- 2014-05-15 EP EP14725114.4A patent/EP3004875B1/en active Active
- 2014-05-15 ES ES14725114T patent/ES2795929T3/es active Active
- 2014-05-15 BR BR112015029852A patent/BR112015029852A2/pt not_active Application Discontinuation
- 2014-05-15 JP JP2016515715A patent/JP6441320B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-15 ZA ZA2015/06813A patent/ZA201506813B/en unknown
- 2015-11-11 IL IL242551A patent/IL242551A/en active IP Right Grant
-
2016
- 2016-04-20 HK HK16104519.6A patent/HK1216779A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2016526164A (ja) | 2016-09-01 |
EP3004875A1 (en) | 2016-04-13 |
ES2795929T3 (es) | 2020-11-25 |
IL242551A (en) | 2017-07-31 |
KR20150129860A (ko) | 2015-11-20 |
US10006032B2 (en) | 2018-06-26 |
RU2672358C2 (ru) | 2018-11-14 |
CN105247365B (zh) | 2019-06-18 |
AU2014273400B2 (en) | 2017-02-23 |
DK3004875T3 (da) | 2020-06-08 |
MX2015016305A (es) | 2016-03-21 |
CN110201156A (zh) | 2019-09-06 |
BR112015029852A2 (pt) | 2017-07-25 |
HK1216779A1 (zh) | 2016-12-02 |
EP3004875B1 (en) | 2020-03-04 |
WO2014191222A1 (en) | 2014-12-04 |
MX365512B (es) | 2019-06-05 |
GB201309657D0 (en) | 2013-07-17 |
ZA201506813B (en) | 2017-01-25 |
CN105247365A (zh) | 2016-01-13 |
PL3004875T3 (pl) | 2020-11-16 |
US20160115479A1 (en) | 2016-04-28 |
CA2907980A1 (en) | 2014-12-04 |
KR101937442B1 (ko) | 2019-01-11 |
GB2514591A (en) | 2014-12-03 |
AU2014273400A1 (en) | 2015-10-08 |
RU2015150739A (ru) | 2017-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6441320B2 (ja) | がん治療のための予測的バイオマーカー | |
JP7138372B2 (ja) | 診断および療法のためのエキソソーム中のゲノムdna、rnaおよびタンパク質の分析 | |
JP6247253B2 (ja) | 白血病幹細胞マーカー | |
Fűri et al. | Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspects | |
WO2006054129A1 (en) | Improved treatment of cancer by double-stranded rna | |
Bienkowska et al. | Cancer-associated fibroblasts in oral cancer: a current perspective on function and potential for therapeutic targeting | |
Belmont et al. | Expression of TLR9 in tumor‐infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer | |
US20200385732A1 (en) | Biomarker for small cell lung cancer therapy | |
Giusti et al. | Extracellular vesicles in prostate cancer: new future clinical strategies? | |
EP2605775A1 (en) | Treatment of liver cancer | |
US20210155933A1 (en) | Tlr-9 agonists for modulation of tumor microenvironment | |
Tanegashima et al. | CXCL14 acts as a specific carrier of CpG DNA into dendritic cells and activates Toll-like receptor 9-mediated adaptive immunity | |
ES2728998T3 (es) | Nuevo antígeno de cáncer EEF2 | |
Gildiz et al. | Nanotechnology-based nucleic acid vaccines for treatment of ovarian cancer | |
Avci‐Adali et al. | In vitro test system for evaluation of immune activation potential of new single‐stranded DNA‐based therapeutics | |
WO2020071489A1 (ja) | 尿路上皮がんを検査する方法 | |
RU2782336C2 (ru) | Способы прогнозирования применимости белков или белковых фрагментов для иммунотерапии | |
Grewal | Characterizing the Acute Immune Response to Cutaneous Peptide Vaccination | |
Cui | Leveraging Macrophages to Develop Cancer Therapeutics | |
JP2024521514A (ja) | がん治療のための順次的な自然免疫調節と適応免疫調節 | |
WO2024015702A1 (en) | Personalized longitudinal analysis of circulating material to monitor and adapt neoantigen cancer vaccines | |
JP2023539332A (ja) | 個別化された免疫原性組成物及びその製造方法及びその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170327 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170718 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171129 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180223 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180427 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180528 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181023 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181121 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6441320 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |